Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) announced today that its Turkish distribution partner, ITEM Medical Technologies, has received a significant new order from the National Ministry of Health as it expands usage of the LuViva® Advanced Cervical Scan...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) announced today that its distributor in Bangladesh has been awarded contracts for four additional LuViva® Advanced Cervical Scan systems for use in the country’s cervical cancer screening program. The latest awards...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it has received notification from the U.S. Food and Drug Administration (FDA) regarding the pre-market approval (PMA) application for the LuViva® Advanced Cervical Scan. In its most recent...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced its operating results for the first quarter ended March 31, 2015. Revenue and other income for the first quarter ended March 31, 2015 was approximately $142,000, including approximately $127,000 in...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), today announced that Stem World Enterprises, its distributor for East Africa, has been awarded a contract with the Nairobi County Health Services Sector to supply the first LuViva® Advanced Cervical Scan for the...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a point-of-care and painless testing platform that uses biophotonics for the early detection of disease that leads to cervical cancer, today announced that it is scheduled to report financial results...
